Ocitinib/Ocitinib

[otw_shortcode_tabslayout tabs=”8″ tab_1_title=”Overview” tab_1_content=”Ocitinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) and has an antitumor effect in non-small cell lung cancer cell lines harboring EGFR mutations cell lines harboring EGFR mutations” tab_2_title=”Indications” tab_2_content=”Ositinib is indicated for locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression on or after prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and confirmed positive for EGFRT790M mutation by testing. lung cancer (NSCLC) in adult patients with locally advanced or metastatic non-small cell carcinoma (NSCLC) with positive EGFRT790M mutation confirmed by testing.” tab_3_title=”Dosage” tab_3_content=”1. Administered orally at the recommended dose of 80 mg daily until disease progression or intolerable toxicity occurs. 2. Dosing may be suspended or reduced depending on the safety and tolerability of the individual patient. If a dose reduction is required, the dose should be reduced to 40 mg once daily. 3. This product should be taken at the same time each day, either with a meal or on an empty stomach. 4. Ocitinib should be taken whole and with water and should not be crushed, broken or chewed. If the patient is unable to swallow the drug, the tablet can be dissolved in 50mL of carbonate-free water without crushing, stirred directly until it is dispersed and swallowed quickly. An additional ½ cup of water should be added to ensure that no residue remains in the cup, followed by rapid consumption. No other liquids should be added. 5. When feeding through a gastric tube, it can be handled in the same way as above, except that 15 ml of water is used for the initial dissolution of the drug and 15 ml for the subsequent rinsing of the residue. 30 ml of this liquid should be fed according to the instructions of the manufacturer of the nasogastric tube and rinsed with an appropriate amount of water. Both these dissolution solutions and residuals should be administered within 30 minutes of adding the tablets to the water.” tab_4_title=”Precautions” tab_4_content=”1. EGFR mutation status should be adequately evaluated before treatment with this product. 2. If patients are suspected of having interstitial lung disease, the drug should be suspended and a full diagnostic workup is strongly recommended. 3. Patients with congenital long QT interval syndrome should avoid the use of this product. 4. Based on available clinical trial data, it is not certain that there is a causal relationship between changes in myocardial contractility and this product. 5. Patients with acute or worsening signs and symptoms of keratitis, such as ocular inflammation, tearing, photophobia, blurred vision, eye pain, and/or red eye, should be referred to an ophthalmologist promptly. 6. This product has no or slight effect on the ability to drive and operate machinery.” tab_5_title=”Contraindications” tab_5_content=”1. Hypersensitivity to the active ingredient or any excipients. 2. must not be taken with St. John’s Wort.” tab_6_title=”Adverse Reactions” tab_6_content=”1. Cardiovascular system: prolonged QT interval, venous thromboembolism, reduced LVEF, cardiomyopathy. 2. metabolic/endocrine system: hyponatremia, hypomagnesemia. 3. Respiratory system: pneumonia, pulmonary embolism, interstitial lung disease, cough. 4. Musculoskeletal system: back pain. 5. Neurological system: cerebral hemorrhage, cerebrovascular accident, cerebral infarction, headache. 6. Gastrointestinal tract: diarrhea, nausea, loss of appetite, constipation, stomatitis. 7. Blood: lymphocytopenia, thrombocytopenia, anemia, neutropenia, leukopenia. 8. Skin: rash, dry skin, itchy skin, nail toxicity. 9. Eyes: dry eyes, blurred vision, keratitis, cataracts, eye irritation, facial rim infection, increased tearing, vitreous humor mosquitoes. 10. other: fatigue.” tab_7_title=”Interactions” tab_7_content=”Food: Ocitinib can be taken with meals or on an empty stomach, with no significant food interactions. Drugs: 1. Potent CYP3A4 inducers may lead to decreased exposure to this product. This product may increase exposure to BCRP substrates. 2. Concomitant use of this product and strong inducers of CYP3A4 (e.g., phenytoin, rifampin, and carbamazepine), and moderate inducers (e.g., bosentan, efavirenz, etravirine, and modafinil) should be avoided. 3. Patients taking this product in combination with drugs that rely on BCRP for distribution and have a narrow therapeutic index (e.g., resulvastatin) should be monitored closely to detect changes in tolerability due to increased exposure to the combined drug in a timely manner.” tab_8_title=”Special Populations” tab_8_content=”Children: the safety and efficacy of this product in pediatric or adolescent patients less than 18 years of age is unknown and caution is advised. Pregnant women and women who may become pregnant: This product should not be used during pregnancy unless the patient’s clinical condition requires treatment with this product. Women of childbearing age should avoid pregnancy while taking this product. Such patients should continue to use effective contraception for at least 2 months for women and 4 months for men after completion of treatment with this product. The risk of decreased exposure to hormonal contraceptives cannot be ruled out with the combination of this product. Breastfeeding women: As it cannot be excluded that this product will have an effect on the breastfed infant. It is recommended that breastfeeding should be discontinued during treatment with this product. Geriatric patients: Good dosing supervision is required during the use of this drug in elderly patients.”] [/otw_shortcode_tabslayout]